In accordance with generally accepted accounting principles, Baxter expects to record a special pre-tax charge of approximately $5 million for in- process research and development associated with the transaction in the fourth quarter of 2007. In addition, Baxter may make future development and sales milestone-related payments to Nektar.
Baxter Hemophilia Research and Development
Baxter is a global leader in hemophilia therapy, with innovations that span 40 years. Through its own scientific expertise and strategic partnerships, Baxter is applying novel technologies that will pioneer the next generation of hemophilia therapies. Baxter's goal is to greatly enhance treatment convenience through therapies that require fewer injections and offer non-intravenous dosing alternatives.
About Hemophilia and Hemophilia B
People with hemophilia do not produce adequate amounts of Factor VIII or Factor IX protein, which are necessary for blood to effectively clot. If untreated, patients with severe hemophilia have a greatly reduced life expectancy. According to the World Health Organization, more than 400,000 people in the world have hemophilia, corresponding to an incidence of 15 to 20 in every 100,000 males born worldwide. Hemophilia B is largely an inherited disorder in which the Factor IX protein needed to form blood clots is missing or reduced. In approximately 30 percent of cases, there is no family history of the disorder and the condition is the result of a spontaneous gene mutation. The first diagnosis of hemophilia B occurred in 1952.
Baxter International Inc., through its subsidiaries, assists healthcare
professionals and their patients with the treatment of complex medical
conditions, including cancer, hemophilia, immune disorders, kidney disease
and trauma. The company applies its expertise in medical devices,
pharmaceuticals and bio
|SOURCE Baxter International Inc.|
Copyright©2008 PR Newswire.
All rights reserved